Nativis Inc.

founded in 2002 and headquartered in seattle, wa, emulate therapeutics is a clinical-stage therapeutic device company. emulate therapeutics has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulrfe®) to specifically regulate signaling and metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called emulate therapeutics voyager. the company’s goal is to transform disease treatment on a global scale with ulrfe®. the proprietary technology has the potential to be applied to a wide range of conditions as well as veterinary medicine and non-medical applications. emulate therapeutics’ initial focus is on the treatment of patients with brain cancer who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. additional pre-clinical work is focused on explorin